Type 1 interferons as a potential treatment against COVID-19.
Identifieur interne : 000321 ( Main/Exploration ); précédent : 000320; suivant : 000322Type 1 interferons as a potential treatment against COVID-19.
Auteurs : Erwan Sallard [France] ; François-Xavier Lescure [France] ; Yazdan Yazdanpanah [France] ; France Mentre [France] ; Nathan Peiffer-Smadja [France]Source :
- Antiviral research [ 1872-9096 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (usage thérapeutique), Betacoronavirus (isolement et purification), Humains (MeSH), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Interféron de type I (usage thérapeutique), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie).
- MESH :
- isolement et purification : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Interféron de type I.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents, Interferon Type I.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Humans, Pandemics.
Abstract
Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.
DOI: 10.1016/j.antiviral.2020.104791
PubMed: 32275914
PubMed Central: PMC7138382
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Type 1 interferons as a potential treatment against COVID-19.</title><author><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name><affiliation wicri:level="3"><nlm:affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32275914</idno><idno type="pmid">32275914</idno><idno type="doi">10.1016/j.antiviral.2020.104791</idno><idno type="pmc">PMC7138382</idno><idno type="wicri:Area/Main/Corpus">001763</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001763</idno><idno type="wicri:Area/Main/Curation">001763</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001763</idno><idno type="wicri:Area/Main/Exploration">001763</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Type 1 interferons as a potential treatment against COVID-19.</title><author><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name><affiliation wicri:level="3"><nlm:affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name><affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Antiviral research</title><idno type="eISSN">1872-9096</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (isolation & purification)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Humans (MeSH)</term><term>Interferon Type I (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Betacoronavirus (isolement et purification)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Interféron de type I (usage thérapeutique)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon Type I</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron de type I</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32275914</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res.</ISOAbbreviation></Journal><ArticleTitle>Type 1 interferons as a potential treatment against COVID-19.</ArticleTitle><Pagination><MedlinePgn>104791</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0166-3542(20)30205-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2020.104791</ELocationID><Abstract><AbstractText>Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sallard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lescure</LastName><ForeName>François-Xavier</ForeName><Initials>FX</Initials><AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdanpanah</LastName><ForeName>Yazdan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mentre</LastName><ForeName>France</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peiffer-Smadja</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Interferon</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32275914</ArticleId><ArticleId IdType="pii">S0166-3542(20)30205-9</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2020.104791</ArticleId><ArticleId IdType="pmc">PMC7138382</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name></region><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000321 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000321 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32275914
|texte= Type 1 interferons as a potential treatment against COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32275914" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |